Overview

Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid

Status:
Completed

Trial end date:
2019-07-13

Target enrollment:
0

Participant gender:
All

Summary

This study will evaluate patients with diagnosis of polypoidal choroidal vasculopathy (PCV) in pachychoroid treated with combined therapy, consisting in photodynamic therapy (PDT) and 3 intravitreal therapy (IVT) of Aflibercept monthly. This is a single center, prospective case-series study. The investigators are going to evaluate Corrected Distance Visual Acuity (CDVA), disease activity, retinal and choroidal thicknesses and number of injection per year, during a twelve month follow up. The aim of this study is to verify if the combined therapy can act on the insult induced by the pachychoroid and on the neovascular lesion itself in this sub-population of patients with PCV in pachychoroid,

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo

Treatments:

Aflibercept
Verteporfin

Criteria

Inclusion Criteria:

- presence of haemorrhagic or exudative PCV diagnosed by OCT and ICGA

- Mean central choroidal thickness > 250 µm

Exclusion Criteria:

- ocular comorbidity

- previous cardiovascular events

- different ocular surgical procedures form cataract surgery